Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Seems highly unlikely they've forgotten to schedule a meeting given they want to press on. I believe every RNS relating to dosing has been issued on a Weds or Thurs so hopefully we get news this week.
Their previous method has been to announce the 1st/3rd patient dosed when starting/restarting a trial (which Alan had done, with an anticipated SDMC review by the end of April), then at each SDMC decision to escalate the dose. It could be of course that no one was tasked with scheduling an SDMC meeting.
A cheap petty whine BV.
BV it depends on if they intend on an RNS for safety committee happy to proceed, 1st patient dosed or 3rd patient dosed.
The RNS announcement of Christina Coughlin, MD, PhD, being appointed Chief Executive Officer of Avacta Group stated that “Appointment reflects Avacta's focus on maximizing value from the pre|CISIONTM platform for the treatment of cancer”.
This to me seems to be a clear move away from the previous CEO who was focusing to much on the diagnostic division and acknowledging the mistake he made to plunge more funds into adding loss making business to that division while the clear value driver seems clear to others to be development of the pre|CISION™ platform.
Dr. Coughlin assumed the role of Head of Research and Development in February 2024, driving the development of the pre|CISION™ platform.
Give the girl a chance. She's had her feet under the desk for just four working days .....with a ton of stuff to review no doubt.
Still nothing. It's beginning to look like a patient has dropped out.
Thorn
Define merit?
CC knows Novartis key players
CC trusts that she won’t be dumped 12 months after the TO
Avacta would be a nice fit with Novartis
Novartis have the funds
Novartis aren’t so big that Avacta will be swallowed up and lost
This isn’t about who will pay the most
I posted a good few weeks back that I thought (conjecture) that CC’s role as head of development was a stipulation of Novartis TO offer.
Yes all guesswork on my part. Time will tell
LR19129 still listed in the LG Chem pipeline
https://innovation.lgchem.com/ResearchDevelopment/Pipeline.do
https://www.lgchem.com/company/company-information/business-domain/biology?lang=en_US
Eliot has connections with this company too...
https://biogenerationventures.com/en/
Oh and BTW the founder of Levicept was made CSO when Eliot took over his CEO position.
Below is what happened at Levicept after their fundraise... founder dumped in favour of Eliot Forster...did the European fund have anything to do with AS being dumped. If Eliot bought the European fund to the table and they dictated price with much more funding to follow based on trial results, CEO upgrade, a place on the Board.
December 2023
Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator, LEVI-04
November 2023
Levicept Appoints Eliot Forster as CEO
October 2022
First patient dosed in multicentre Phase II study of LEVI-04 in osteoarthritis patients. Multiple arm, multi-centre, placebo-controlled study to evaluate five monthly infusions of LEVI-04 for the treatment of pain due to osteoarthritis of the knee. ClinicalTrials.gov ID: NCT05618782
April 2022
Case Study interview with Simon Westbrook, CEO of Levicept in Bioprocess Online discussing his experience in selecting and working with a global CDMO partner, and the value Lonza brought to his virtual company.
https://www.bioprocessonline.com/doc/illustrating-a-successful-small-biotech-cdmo-relationship-0002
September 2021
Closing of £35m Series B financing. All existing investors – Medicxi, Advent Life Sciences and Gilde Healthcare – participate, joined by Pfizer Ventures. Funds to support further development of LEVI-04 including Phase II study.
March 2021
Phase I clinical trial of LEVI-04 successfully completed. Study in osteoarthritis patients confirmed favourable safety, tolerability and pharmacokinetic profile. Analysis of biomarkers indicated target engagement and provided early supporting evidence of efficacy / proof-of-concept. ClinicalTrials.gov ID: NCT03227796
I think that's the point Touk.
Deals will be done on merit, not who has the next door office?
Apart from CC and the bloke who can’t add up.
Heavily over weight on Diagnostics leadership Team.
THERAPEUTICS LEADERSHIP TEAM
Christina Coughlin
Chief Executive Officer
Tony Gardiner
Chief Financial Officer
Karen Harrison
Chief Operating Officer, Therapeutics
Simon Bennett
Chief Business Officer, Therapeutics
DIAGNOSTICS LEADERSHIP TEAM
Christina Coughlin
Chief Executive Officer
Tony Gardiner
Chief Financial Officer
Craig Slater
Chief Operating Officer, Diagnostics
Matt Johnson
Chief Scientific Officer, Diagnostics
David Wilson
Chief Commercial Officer, Diagnostics
Anne McGurk
Joint Managing Director, Launch Diagnostics
Ian Jones
Joint Managing Director, Launch Diagnostics
BIOGRAPHY
Cathy Fiatte
Directrice Générale, Launch Diagnostics France SAS
Sébastien Goenen
Chief Operating Officer, Coris BioConcept
Did GSA Capital partners open their short position on the back of the rather strange bearish note written by Deutshe Bank (Numis))
Just add if it’s a low ball, clean up the shop offer I’d be unhappy too…
Lot of conjecture here on AS .
IMHE. Either financial backers sought this , OR Alastair disagreed with an approach proposal which is warming up and being supported by remaining board.
Happens a lot.
Wish AS well, it’s no mean feat to start a company like this and see it through to a decent stage .
GLA
That's a lousy poem
Ipadtrader --------
Bluntly put ------ but true.
I think like the majority here I was glad to see the removal of AS, for too long he has shown a serious lack of business acumen and actually why would that be a surprise he is after all a scientist and I don't even know if he was a good one because the original tech he had been treating as a science project for many years wasn't actually his own work anyway.
Obviously there is no reason why some scientists can't become good CEO's ...will CC be a good CEO...I don't know time will tell but what I do think is the BoD are now well aware that the company could no longer continue trundling on ignoring the fact that ultimately its first responsibility is its shareholders.....and that means commerciality.
Who could possibly own the bond? Is it owned by Heights? Or by one of their clients?
Alongside the CFO , I also question the Chairman’s judgement.
Whilst Dr Coughlin has impressive scientific and clinical experience, it’s her business skills that will now come under scrutiny. A CEO at CytoImmune which lasted less than 2 years isn’t a ringing endorsement. Would have preferred she retained her clinical role but maybe few external candidates were that attracted, so rather than wait EF decided upon a hasty solution with AS probably setting the deadline. Hence now acknowledges more weight is still needed .
WeAreGroot -
I think most are agreed we need a new CFO, someone who CC is satisfied with, and doesn't publish an RNS proving simple arithmetic is an issue.
Someone perhaps with experience gained in USA, with US contacts and has knowledge of rules / regs and trading on US exchanges, as CC must recognise some of AIM's limitations and problems by now.
You mention CC '....presented the best proposed strategy and credentials'.
If she did, she may have presented to members of the present board, and some of these people may soon find themselves applying for other jobs.
Intriguing
Always had my doubts about you timster
Keep up the good work while you can
12) Seemingly no bank holidays IN THE ROOM. Poor sods. Tough times in TWs sweat shop. Give them a day off you heartless toothless animal.
Have you been on the pop today watching?